

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 April 2010 (29.04.2010)

(10) International Publication Number
WO 2010/046835 A1

PCT

(51) International Patent Classification:

C07D 277/54 (2006.01) **A61P 37/06** (2006.01)
A61K 31/426 (2006.01) **A61P 35/00** (2006.01)
A61P 3/10 (2006.01) **A61P 35/04** (2006.01)
A61P 29/00 (2006.01) **A61P 37/00** (2006.01)

(21) International Application Number:

PCT/IB2009/054592

(22) International Filing Date:

19 October 2009 (19.10.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0819182.7 20 October 2008 (20.10.2008) GB

(71) Applicant (for all designated States except US): **ACTELION PHARMACEUTICALS LTD** [CH/CH];
Gewerbstrasse 16, CH-4123 Allschwil (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BONHAM, Nicholas** [GB/GB]; 17 Waterhouse, Chesterton, Cambridge Cambridgeshire CB4 1XZ (GB). **BUCHMANN, Stephan** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH). **EBERLIN, Alex** [GB/GB]; Stanley Road, Cambridge Cambridgeshire CB5 8LW (GB). **IMBODEN, Christoph** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **VON RAUMER,**

Markus [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).

(74) Agent: **GSCHWEND, Thomas**; c/o Actelion Pharmaceuticals Ltd., Legal Department, Gewerbstrasse 16, CH-4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE FORMS OF (R) -5- [3-CHLORO-4- (2, 3-DIHYDROXY-PROPOXY) -BENZ [Z] YLIDENE] -2- ([Z] -PROPYLIMINO) -3-0-TOLYL-THIAZOLIDIN-4-ONE

(57) Abstract: The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.



WO 2010/046835 A1